Free Trial
LON:YGEN

Yourgene Health (YGEN) Share Price, News & Analysis

Yourgene Health logo

About Yourgene Health Stock (LON:YGEN)

Key Stats

Today's Range
N/A
50-Day Range
0.52
0.52
52-Week Range
N/A
Volume
13.15 million shs
Average Volume
21.98 million shs
Market Capitalization
£16.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient's response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing. In addition, it provides genomic services; sample preparation and analysis tools; and bioinformatics and software products, as well as extraction for DNA, RNA/miRNA, and nucleons; quantification; genotyping; gene expression; methylation; and microarray services for clinical research organizations. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. Yourgene Health Plc was incorporated in 2000 and is headquartered in Manchester, the United Kingdom. As of September 8, 2023, Yourgene Health Plc operates as a subsidiary of Novacyt UK Holdings Limited.

Receive YGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yourgene Health and its competitors with MarketBeat's FREE daily newsletter.

YGEN Stock News Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Best Portable Oxygen Concentrators
See More Headlines

YGEN Stock Analysis - Frequently Asked Questions

Shares of YGEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yourgene Health investors own include HSBC (HSBA), Imperial Brands (IMB), Antofagasta (ANTO), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Barclays (BARC) and B&M European Value Retail (BME).

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
253
Year Founded
N/A

Profitability

Net Income
£-8,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£29.67 million
Book Value
GBX 4 per share

Miscellaneous

Outstanding Shares
3,190,000,000
Free Float
N/A
Market Cap
£16.43 million
Optionable
Not Optionable
Beta
0.86
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (LON:YGEN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners